Boston Scientific Corporation has announced the launch and first U.S. implant of its line of Extended Longevity implantable cardioverter defibrillators, including DYNAGEN™ EL and INOGEN™ EL device models.
The benefits of increased longevity from an ICD are pretty clear. By avoiding replacement procedures the device reduces the risk of infection and other complications over time, minimizes out-of-pocket patient expenses, and decrease other healthcare system costs associated with device therapy.
Boston Scientific’s Extended Longevity (EL) implantable cardioverter defibrillators (ICD)device features EnduraLife™ battery technology that was developed with high-performance chemistry and advanced manufacturing capabilities to provide up to double the battery capacity of other ICDs. The EL ICD is projected to last nearly 12 years according to its technical manual.
The company cites references that suggest its EnduraLife battery technology delivers the industry’s longest projected longevity, all packaged in a device up to 11 percent smaller and 24 percent thinner than devices from other manufacturers.
The first EL ICD was implanted at The University of Pittsburgh Medical Center (UPMC) by Dr. Samir Saba.
“Battery longevity has a direct impact on patient outcomes and the cost of care,” said Dr. Saba. “The EL ICD is an important advancement that can help minimize the frequency of avoidable replacement procedures to help reduce costs and the potential for replacement-related complications.”
“Boston Scientific is proud to build upon the world’s most innovative ICD technology with the world’s smallest ICD, the world’s longest-lasting ICD and the world’s only subcutaneous ICD,” said Joe Fitzgerald, executive vice president and president, Rhythm Management. “By providing a device with greater battery capacity, physicians are now able to offer patients a longer lasting device and increased peace of mind, while administrators and payors have new options to more effectively manage healthcare costs and minimize unexpected complications.”
Source: PR Newswire